The forecasts have been fulfilled. GSK’s respiratory syncytial virus (RSV) vaccine has become best seller in less than a year. The antigen from the British laboratory has achieved sales more than 1,000 million euros.
According to the results published recently by the pharmaceutical company, sales of Arexvy (trade name for the RSV vaccine) have risen to 1,455 million euros (1,238 million pounds).
Already in November, the company’s CEO, Emma Walmsley, said that GSK hoped that its antigen against this respiratory virus that causes bronchiolitis would become a blockbuster.
[España ya estudia la financiación de las vacunas contra el virus respiratorio sincitial para adultos]
At that time, it predicted sales of between 900 and 1,000 million pounds (1,140-1,270 million dollars at the current exchange rate). It should be remembered that a drug is considered a best-seller when its turnover exceeds 1 billion dollars.
Finally, the antigen has exceeded the pharmaceutical company’s forecasts, exceeding 1.2 billion pounds. And all this in less than a year. The vaccine was approved for use in the United States in May of last year and is indicated for people over 60 years of age. In Europe, the authorization came somewhat later, in June 2023.
GSK vs. Pfizer
As EL ESPAÑOL-Invertia published, GSK won the first battle against Pfizer in VRS. The vaccine british billed 488 million more in the third quarter of 2023. An advantage that has increased up to 624 million euros at the end of the year.
While the GSK preparation generated sales of more than 1.4 billion euros, those of the Pfizer vaccine remained at 831 million euros ($890 million). It should be remembered that the American multinational’s antigen received authorization for use a month after GSK’s in the US.
Archive image of a vaccine iStock
Airfinity’s long-term forecasts are that GSK’s vaccine continues to lead the market. All this despite the fact that Pfizer’s antigen has an ‘advantage’ over GSK’s. While the one from the British company is indicated only for people over 60 years of age (its authorization in the age group of 50 to 59 years in the US is being studied), Pfizer’s also adds pregnant women.
The goal is to protect babies from RSV (the virus that causes bronchiolitis). And this is where another competitor arises for Pfizer: Sanofi and its monoclonal antibody against RSV for babies, Beyfortus.
Follow the topics that interest you
2024-02-14 01:31:53
#GSKs #respiratory #syncytial #virus #vaccine #bestseller #year
